ASH Letter re FDA's Draft Guidance on Assessment of Overall Survival in Oncology Clinical Trials

American Society of Hematology. (2025).
ASH Letter re FDA's Draft Guidance on Assessment of Overall Survival in Oncology Clinical Trials.
Retrieved from https://www.hematology.org/advocacy/testimony-and-correspondence/ash-letter-re-fdas-draft-guidance-on-assessment-of-overall-survival-in-oncology-clinical-trials.

American Society of Hematology.
"ASH Letter re FDA's Draft Guidance on Assessment of Overall Survival in Oncology Clinical Trials." Hematology.org.
https://www.hematology.org/advocacy/testimony-and-correspondence/ash-letter-re-fdas-draft-guidance-on-assessment-of-overall-survival-in-oncology-clinical-trials
(label-accessed October 19, 2025).

"American Society of Hematology."
ASH Letter re FDA's Draft Guidance on Assessment of Overall Survival in Oncology Clinical Trials, 19 Oct. 2025 ,
https://www.hematology.org/advocacy/testimony-and-correspondence/ash-letter-re-fdas-draft-guidance-on-assessment-of-overall-survival-in-oncology-clinical-trials.

Citation Manager Formats

• BibLaTeX
• Bookends
• EasyBib
• EndNote
• Mendeley
• Papers
• RIS
• Ref Manager
• RefWorks
• Zotero